Status:
COMPLETED
Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors
Lead Sponsor:
Centre Oscar Lambret
Collaborating Sponsors:
Roche Pharma AG
Conditions:
Metastatic Colorectal Cancer
Non-Small-Cell Lung Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Patients will receive local prophylactic treatment (Diprosone cream) during 8 weeks from the beginning of the EGF-R inhibitors treatment, on the areas of the body susceptible to be affected by follicu...
Eligibility Criteria
Inclusion
- Indication of Cetuximab in patients with metastatic colorectal cancer in association or not with irinotecan, after failure of a chemotherapy treatment with Irinotecan OR
- Indication of Erlotinib, in patients with metastatic Non-Small-Cell Lung Carcinoma, after failure of at least one chemotherapy treatment
- No pre-existing cutaneous toxicity
Exclusion
- Contraindication to local corticotherapy
- Previous history of severe hypersensibility reactions (Grade III or IV) due to Cetuximab, Irinotecan or Erlotinib
- Betamethasone or one of excipient product allergy
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00910676
Start Date
October 1 2007
End Date
March 1 2009
Last Update
July 31 2012
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Oscar Lambret
Lille, France, 59020
2
Centre Hospitalier Regional
Lille, France, 59035
3
Centre Hospitalier Régional
Lille, France, 59035